{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Harmony Biosciences Holdings, Inc."},"Symbol":{"label":"Symbol","value":"HRMY"},"Address":{"label":"Address","value":"630 W. GERMANTOWN PIKE,SUITE 215, PLYMOUTH MEETING, Pennsylvania, 19462, United States"},"Phone":{"label":"Phone","value":"+1 484 539-9800"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The companys product WAKIX pitolisant is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy."},"CompanyUrl":{"label":"Company Url","value":"https://www.harmonybiosciences.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Bradshaw","title":"Head-Technical Operations"},{"name":"Jeffrey M. Dayno","title":"President, Chief Executive Officer & Director"},{"name":"Kumar Budur","title":"Chief Medical & Scientific Officer, Executive VP"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}